Uploaded November 2026 | Updated November 2026, 2 days ago
A 22 year old soccer player with no symptoms walks into a clinic for a routine sports physical and walks out being told to quit his sport.
Dr. Baraki takes this mystery case blind and we hand him the pieces one at a time: the EKG, the echocardiogram, the cardiac MRI, the Holter monitor, the treadmill test and the genetic panel. Half of them come back completely normal. Play along and commit to an answer before the reveal, because there is a point in this case where most people would change theirs.
Then, the discussion about whether the restriction he was given was the right call, what the evidence on that says today compared with what it said for the previous 40 years, and why two doctors looking at the same numbers can reasonably land in different places.
And then screening. Should an EKG should be mandatory for amateur athletes? All this and more, on this episode of the Barbell Medicine Podcast.
Timestamps
• 00:00 A 22-year-old needs a form signed
• 02:16 The history and exam
• 05:49 Reading his EKG
• 13:13 The echo and the MRI
• 18:26 The rest of the workup, and Austin commits to a diagnosis
• 24:02 Patient course
• 27:54 What his care team decided
• 29:45 How much the heart changes with training
• 36:45 A second case that went differently
• 41:52 Should a finding like this end a career
• 45:47 Should an EKG be mandatory for amateur athletes
• 55:59 What would actually move the needle
Resources
Buy the book, Signal: barbellmedicine.com/shop/learning/signal
Free Vital 5 Action Plan (barbellmedicine.com/vital-5-action-plan/)
New Barbell Medicine Hybrid 5K and 10K Run + Lift Programs (barbellmedicine.com/shop/training-templates/endurance/hybrid-5k-10k/)
Barbell Medicine coaching and templates: barbellmedicine.com
Get early access, ad-free listening, and exclusive content here: barbellmedicine.supercast.com
1. Marques JP, Freitas A, Abecasis J. Beware of regression of electrocardiographic abnormalities on detraining: it may not always mean "athlete's heart." Rev Port Cardiol (Engl Ed). 2021;40(10):801.e1-801.e6. doi:10.1016/j.repce.2021.10.012. PMID 34857120.
2. Pelliccia A, Maron BJ, Culasso F, et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation. 2000;102(3):278-284. doi:10.1161/01.cir.102.3.278. PMID 10899089.
3. Papadakis M, Carre F, Kervio G, et al. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin. Eur Heart J. 2011;32(18):2304-2313. doi:10.1093/eurheartj/ehr140. PMID 21613263.
4. Schnell F, Riding N, O'Hanlon R, et al. Recognition and significance of pathological T-wave inversions in athletes. Circulation. 2015;131(2):165-173. doi:10.1161/CIRCULATIONAHA.114.011038. PMID 25583053.
5. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi:10.1016/S0140-6736(20)31792-X. PMID 32871100.
6. Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med. 2024;390(20):1849-1861. doi:10.1056/NEJMoa2401424. PMID 38739079.
7. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002;346(11):793-801. doi:10.1056/NEJMoa011858. PMID 11893790.
8. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e558-e631. doi:10.1161/CIR.0000000000000937. PMID 33215931.
9. Lopes LR, Ho CY, Elliott PM. Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice. Eur Heart J. 2024;45(30):2727-2734. doi:10.1093/eurheartj/ehae421. PMID 38984491.
10. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med. 2019;12(2):e002460. doi:10.1161/CIRCGEN.119.002460. PMID 30681346.
11. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991;324(5):295-301. doi:10.1056/NEJM199101313240504. PMID 1824720.
12. Spirito P, Pelliccia A, Proschan MA, et al. Morphology of the "athlete's heart" assessed by echocardiography in 947 elite athletes representing 27 sports. Am J Cardiol. 1994;74(8):802-806. doi:10.1016/0002-9149(94)90439-1. PMID 7942554.
13. Powers JM, Lim MY, Achebe MO, et a...
A 22 year old soccer player with no symptoms walks into a clinic for a routine sports physical and walks out being told to quit his sport.
Dr. Baraki takes this mystery case blind and we hand him the pieces one at a time: the EKG, the echocardiogram, the cardiac MRI, the Holter monitor, the treadmill test and the genetic panel. Half of them come back completely normal. Play along and commit to an answer before the reveal, because there is a point in this case where most people would change theirs.
Then, the discussion about whether the restriction he was given was the right call, what the evidence on that says today compared with what it said for the previous 40 years, and why two doctors looking at the same numbers can reasonably land in different places.
And then screening. Should an EKG should be mandatory for amateur athletes? All this and more, on this episode of the Barbell Medicine Podcast.
Timestamps
• 00:00 A 22-year-old needs a form signed
• 02:16 The history and exam
• 05:49 Reading his EKG
• 13:13 The echo and the MRI
• 18:26 The rest of the workup, and Austin commits to a diagnosis
• 24:02 Patient course
• 27:54 What his care team decided
• 29:45 How much the heart changes with training
• 36:45 A second case that went differently
• 41:52 Should a finding like this end a career
• 45:47 Should an EKG be mandatory for amateur athletes
• 55:59 What would actually move the needle
Resources
Buy the book, Signal: barbellmedicine.com/shop/learning/signal
Free Vital 5 Action Plan (barbellmedicine.com/vital-5-action-plan/)
New Barbell Medicine Hybrid 5K and 10K Run + Lift Programs (barbellmedicine.com/shop/training-templates/endurance/hybrid-5k-10k/)
Barbell Medicine coaching and templates: barbellmedicine.com
Get early access, ad-free listening, and exclusive content here: barbellmedicine.supercast.com
1. Marques JP, Freitas A, Abecasis J. Beware of regression of electrocardiographic abnormalities on detraining: it may not always mean "athlete's heart." Rev Port Cardiol (Engl Ed). 2021;40(10):801.e1-801.e6. doi:10.1016/j.repce.2021.10.012. PMID 34857120.
2. Pelliccia A, Maron BJ, Culasso F, et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation. 2000;102(3):278-284. doi:10.1161/01.cir.102.3.278. PMID 10899089.
3. Papadakis M, Carre F, Kervio G, et al. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin. Eur Heart J. 2011;32(18):2304-2313. doi:10.1093/eurheartj/ehr140. PMID 21613263.
4. Schnell F, Riding N, O'Hanlon R, et al. Recognition and significance of pathological T-wave inversions in athletes. Circulation. 2015;131(2):165-173. doi:10.1161/CIRCULATIONAHA.114.011038. PMID 25583053.
5. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi:10.1016/S0140-6736(20)31792-X. PMID 32871100.
6. Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med. 2024;390(20):1849-1861. doi:10.1056/NEJMoa2401424. PMID 38739079.
7. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002;346(11):793-801. doi:10.1056/NEJMoa011858. PMID 11893790.
8. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e558-e631. doi:10.1161/CIR.0000000000000937. PMID 33215931.
9. Lopes LR, Ho CY, Elliott PM. Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice. Eur Heart J. 2024;45(30):2727-2734. doi:10.1093/eurheartj/ehae421. PMID 38984491.
10. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med. 2019;12(2):e002460. doi:10.1161/CIRCGEN.119.002460. PMID 30681346.
11. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991;324(5):295-301. doi:10.1056/NEJM199101313240504. PMID 1824720.
12. Spirito P, Pelliccia A, Proschan MA, et al. Morphology of the "athlete's heart" assessed by echocardiography in 947 elite athletes representing 27 sports. Am J Cardiol. 1994;74(8):802-806. doi:10.1016/0002-9149(94)90439-1. PMID 7942554.
13. Powers JM, Lim MY, Achebe MO, et a...










